Skip to main content

Table 3 Pooled estimates of the Network meta-analysis for ORR (lower triangle) and CBR (upper triangle)

From: Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis

AI

1.67 (0.55,5.06)

1.88 (0.99,3.59)

1.47 (0.52,4.18)

1.97 (0.91,4.27)

0.68 (0.46,1.01)

dalpi + Al

1.13 (0.31,4.06)

0.88 (0.19,4.03)

1.18 (0.31,4.56)

0.73 (0.57,0.94)

1.08 (0.68,1.73)

palbo + Al

0.78 (0.23,2.67)

1.05 (0.38,2.87)

0.55 (0.39,0.76)

0.81 (0.48,1.35)

0.74 (0.49,1.12)

ribo + AI

1.34 (0.37,4.92)

0.49 (0.35,0.68)

0.72 (0.43,1.20)

0.66 (0.44,1.00)

0.89 (0.56,1.42)

abema + AI

  1. dalpi dalpiciclib, palbo palbociclib, abema abemaciclib, ribo ribociclib, AI Aromatase inhibitor, ORR Objective response rate, CBR Clinical benefit rate
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us